Obesity related hyperinsulinaemia and hyperglycaemia and cancer development
Obesity related hyperinsulinaemia and hyperglycaemia and cancer development
复制标题
DOI：
10.1080/13813450902878054
复制
发表时间：
2009-01-01
影响因子：
3
通讯作者：
Kaaks, Rudolf
中科院分区：
文献类型：
--
作者：
Becker, Susen;Dossus, Laure;Kaaks, Rudolf
体重过重加上缺乏身体活动是导致胰岛素抵抗以及相关高血糖和高胰岛素血症的主要决定因素，并进一步导致肿瘤的发生。几项前瞻性流行病学研究表明，体重过重与常见恶性肿瘤（如结肠癌、乳腺癌（绝经后）、子宫内膜癌、胆囊癌、胰腺癌、肾癌和食道癌）之间存在直接关联，但也与较少见的恶性肿瘤（如白血病、多发性骨髓瘤和非霍奇金淋巴瘤）相关。胰岛素抵抗和高胰岛素血症无疑是肥胖与肿瘤发展之间关系的关键生物学机制。抗糖尿病药物二甲双胍除了可以降低胰岛素抵抗外，还具有抗肿瘤特性，并且越来越多地被认为是预防和治疗与肥胖相关的癌症的药物。体重过重、胰岛素抵抗和癌症之间的关联涉及多种生物学途径，例如慢性低度炎症、葡萄糖毒性、AGE 产物代谢和单磷酸腺苷激酶途径。
Excess body weight in combination with physical inactivity is a major determinant for the development of insulin resistance with associated hyperglycaemia and hyperinsulinaemia and further leads to tumour development. Several prospective epidemiological studies have shown a direct association between excess weight and common malignancies, such as colon, breast (post-menopausal), endometrial, gallbladder, pancreatic, kidney and oesophageal cancers, but also less frequent malignancies, such as leukaemia, multiple myeloma and non-Hodgkin lymphoma. Insulin resistance and hyperinsulinaemia are certainly key biological mechanisms underlying the relationship between adiposity and tumour development. The anti-diabetic drug, metformin, in addition to reduction of insulin resistance has also shown anti-tumour properties, and is increasingly being considered as a drug to prevent and treat obesity-related cancers. Several biological pathways have been involved in the association between excess body weight, insulin resistance and cancer, such as chronic low-grade inflammation, glucose toxicity, AGE product metabolism and the adenosine monophosphate kinase pathway.